Blog
RSS FeedPosted by Michael Wonder on 20 Jul 2023
OPEN framework extended to a wider range of medicines
20 July 2023 - EMA has expanded the scope of the OPEN initiative from COVID-19 vaccines and treatments to a ...
Posted by Michael Wonder on 23 May 2023
Biden-Harris Administration announces proposal to advance prescription drug transparency in Medicaid
23 May 2023 - New HHS proposal would shed light on cost of prescription drugs and save states and federal ...
Posted by Michael Wonder on 27 Apr 2023
CADTH, ICER, and NICE release joint position statement on redacting clinical data awaiting publication
24 April 2023 - The position statement is a step toward greater transparency of unpublished data and a tangible outcome ...
Posted by Michael Wonder on 24 Apr 2023
NICE collaborates with international partner agencies to streamline the confidential marking process
24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...
Posted by Michael Wonder on 30 Mar 2023
Clarity around PHARMAC’s priority lists
30 March 2023 - PHARMAC released its first Clarity Report, containing the latest information about medicines, vaccines, and related products ...
Posted by Michael Wonder on 01 Dec 2022
Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
1 December 2022 - At a time when many Americans are clamouring for more transparency into prescription drug pricing, one ...
Posted by Michael Wonder on 21 Nov 2022
Big pharma may have to reveal government deals in WHO's draft pandemic rules
17 November 2022 - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make ...
Posted by Michael Wonder on 13 Oct 2022
Clarity around PHARMAC’s priority lists (October 2022)
13 October 2022 - In March 2022, PHARMAC released its first Pūahoaho (clarity) Report, containing the latest information about its ...
Posted by Michael Wonder on 04 Oct 2022
2022 October price disclosure cycle – confirmed prices and patient savings reports
1 October 2022 - Combination flow-on reduction outcomes reflect confirmed 1 October 2022 prices on the Current Price Disclosure cycle web ...
Posted by Michael Wonder on 24 Aug 2022
Prescription medicines: applications under evaluation
24 August 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...
Posted by Michael Wonder on 28 Jul 2022
To promote innovation, Congress and companies should support drug development cost disclosure
28 July 2022 - Congress should pass the proposed Pharmaceutical Research Transparency Act of 2022 to mandate drug companies provide ...
Posted by Michael Wonder on 04 Jul 2022
2022 October price disclosure cycle – indicative prices
4 July 2022 - Indicative 1 October 2022 prices resulting from the 2022 October Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 26 Jun 2022
Price disclosure 2022 October cycle outcomes summary
24 June 2022 - The summary of price disclosure price reductions for the 2022 October Cycle has now been published on ...
Posted by Michael Wonder on 16 Jun 2022
Former FDA officials call for more transparency for drug approvals
15 June 2022 - The US FDA needs to take a more proactive approach in combatting misinformation and communicating decisions to ...
Posted by Michael Wonder on 08 Jun 2022
Updated price disclosure guidelines, price disclosure webpages and price disclosure dispute resolution process
8 June 2022 - Amendments made to the National Health Act 1953 and National Health (Pharmaceutical Benefits) Regulations 2017 by the ...